Baricitinib (Olumiant)
February 2025
in “
Canadian Journal of Health Technologies
”
TLDR Baricitinib is effective and cost-efficient for treating severe alopecia areata in adults.
The document is a reimbursement review of baricitinib (Olumiant), which is available in 2 mg and 4 mg oral tablets. It is indicated for the treatment of adult patients with severe alopecia areata. The review evaluates the clinical effectiveness, cost-effectiveness, and perspectives of patients and clinicians to inform nonbinding recommendations for reimbursement decisions by Canadian governments, excluding Quebec.